Business Context and Reporting Period
This Form 8-K was filed by Akebia Therapeutics, Inc. on December 14, 2023. The report concerns a material definitive agreement involving the company's wholly-owned subsidiary, Keryx Biopharmaceuticals, Inc., and its manufacturing partner, Siegfried Evionnaz SA.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual agreement extension.
Material Changes
The primary material change is the formal election by Akebia Therapeutics to extend its Master Manufacturing Services and Supply Agreement with Siegfried Evionnaz SA. Previously, the agreement was set to expire on December 31, 2024. Following the written notice provided on December 14, 2023, the term of the agreement has been extended through December 31, 2026.
Outlook and Management Commentary
Management confirmed that all other terms and conditions of the Supply Agreement remain in effect following the extension. The filing does not contain forward-looking financial guidance, risk factors, or commentary on unusual items beyond the execution of this contract extension.
Investor Verification Points
- Verify the specific financial obligations and pricing terms within the extended Supply Agreement.
- Confirm the operational capacity of Siegfried Evionnaz SA to meet manufacturing demands through 2026.
- Review the original Amendment No. 5 dated February 28, 2023, for any conditions precedent to the extension.